Loading...

C4 Therapeutics Inc
NASDAQ:CCCC

Watchlist Manager
C4 Therapeutics Inc Logo
C4 Therapeutics Inc
NASDAQ:CCCC
Watchlist
Price: 7.85 USD +0.26% Market Closed
Updated: Dec 10, 2022

Intrinsic Value

The intrinsic value of one CCCC stock under the Base Case scenario is 5.15 USD. Compared to the current market price of 7.85 USD, C4 Therapeutics Inc is Overvalued by 34%.

The Intrinsic Value is calculated as the average of the two valuation methods:

CCCC Intrinsic Value
Base Case
5.15 USD
Overvaluation 34%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Fundamental Analysis

CCCC Profitability Score
Profitability Due Diligence

C4 Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

Negative 3-Year Average ROE
Negative 3-Year Average ROIC
Negative Free Cash Flow
Negative Operating Income
19/100
Profitability
Score

C4 Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

CCCC Solvency Score
Solvency Due Diligence

C4 Therapeutics Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Low Interest Coverage
Low Altman Z-Score
Long-Term Liabilities
Low D/E
53/100
Solvency
Score

C4 Therapeutics Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Financials
Efficiency
0%
Gross Margin
-220%
Operating Margin
-221%
Net Margin
-221%
FCF Margin
-30%
ROE
-86%
ROIC
Other

CCCC Capital Structure
C4 Therapeutics Inc

Market Capitalization 384M USD
Total Debt 9.1M USD
Minority Interest 0 USD
Preferred Equity 0 USD
Cash and Equivalents 49.6M USD
Short-Term Investments 264M USD
Enterprise Value 79.7M USD

Wall St
Price Targets

CCCC Price Targets Summary
C4 Therapeutics Inc

Wall Street analysts forecast CCCC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CCCC is 23.77 USD with a low forecast of 6.06 USD and a high forecast of 88.2 USD.

Lowest
Price Target
6.06 USD
23% Downside
Average
Price Target
23.77 USD
203% Upside
Highest
Price Target
88.2 USD
1 024% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

CCCC Competitors
C4 Therapeutics Inc

CCCC Suppliers & Customers
C4 Therapeutics Inc

C4 Therapeutics Inc has 4 key suppliers from 2 countries and 4 industries. The majority of these suppliers are located in the United States of America, with the largest number of suppliers in the Life Sciences Tools & Services industry.

C4 Therapeutics Inc has 2 key customers from 1 countries and 2 industries. The majority of these customers are located in the United States of America, with the largest number of customers in the Biotechnology industry.

Ownership

CCCC Insider Trading
Buy and sell transactions by insiders

C4 Therapeutics Inc insiders have sold more shares than they have bought in the past 12 months.

During the last 12 months C4 Therapeutics Inc insiders bought 84k USD , and sold 498k USD worth of shares. The last transaction was made on Dec 10, 2022 by Hirsch Andrew (President & CEO), who bought 84k USD worth of CCCC shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
0 USD
0
9-12
months
498k USD
2
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
1
84k USD
9-12
months
0
0 USD
Cumulative Transactions Amount
Period Sold Bought Net
3 Months
N/A
N/A
N/A
6 Months
N/A
N/A
N/A
9 Months
N/A
84k USD
84k
12 Months
498k USD
84k USD
-413.8k
Purchases
4
Sales
35
Why is insider trading important?

Shareholder Return

CCCC Price
C4 Therapeutics Inc

1M 1M
-11%
6M 6M
+31%
1Y 1Y
-77%
3Y 3Y
-59%
5Y 5Y
-59%
Annual Price Range
7.85
52w Low
5.06
52w High
34.37
Price Metrics
Average Annual Return 68.21%
Standard Deviation of Annual Returns
N/A
Max Drawdown -90%
Shares Statistics
Market Capitalization 384M USD
Shares Outstanding 48 957 000
Percentage of Shares Shorted 9.08%

Company Profile

C4 Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

384M USD

Dividend Yield

0%

Description

C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. The company is headquartered in Watertown, Massachusetts and currently employs 121 full-time employees. The company went IPO on 2020-10-02. The firm is focused on harnessing the body’s natural regulation of protein levels to develop therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. The firm provides technology platform, Target ORiented ProtEin Degrader Optimizer (TORPEDO), to synthesize a new class of small molecule protein degraders that are designed to destroy disease-causing proteins, including targets previously considered to be undruggable. The Company’s lead product candidates, CFT7455, is an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma (MM), peripheral T-cell lymphoma (PTCL), and mantle cell lymphoma (MCL). The firm is also developing CFT8634, an orally bioavailable degrader of a protein target called bromodomain containing 9 (BRD9), for synovial sarcoma and SMARCB1-deleted solid tumors.

Contact

MASSACHUSETTS
Watertown
490 Arsenal Way, Suite 200
+16172310700.0
https://c4therapeutics.com/

IPO

2020-10-02

Employees

121

Officers

CEO, Pres & Director
Mr. Andrew J. Hirsch
Co-Founder, Independent Director & Member of Scientific Advisory Board
Dr. Kenneth C. Anderson M.D., Ph.D.
Chief Financial Officer
Ms. Lauren A. White
Chief Scientific Officer
Dr. Stewart Fisher
Chief Legal Officer
Ms. Jolie M. Siegel J.D.
Chief Medical Officer
Dr. Adam S. Crystal M.D., Ph.D.
Show More
Co-Founder & Member of Scientific Advisory Board
Dr. Nathanael S. Gray Ph.D.
Sr. VP of Communications & Investor Relations
Ms. Kendra Adams
Director of HR
Kristina Zambouras
Chief People Officer
Ms. Kelly Schick
Show Less

See Also

Similar Stocks
What is the Intrinsic Value of one CCCC stock?

The intrinsic value of one CCCC stock under the Base Case scenario is 5.15 USD.

Is CCCC stock undervalued or overvalued?

Compared to the current market price of 7.85 USD, C4 Therapeutics Inc is Overvalued by 34%.